Prot #ETCTN 10107/MC1721: Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and MK-3475 (Pembrolizumab) Compared to MK-3475 (Pembrolizumab) Alone for Mesothelin-Positive Malignant Pleural Mesothelioma

Project: Research project

Project Details

StatusFinished
Effective start/end date7/21/20 → 8/30/21

Funding

  • Leidos Biomedical Research, Inc. (Prot #ETCTN 10107/MC1721 // Prot #ETCTN 10107/MC1721)
  • Bayer HealthCare Pharmaceuticals, Inc. (Prot #ETCTN 10107/MC1721 // Prot #ETCTN 10107/MC1721)